ODYSSEY COMBO II | Clinical Trial - ODYSSEY COMBO II

Description:

The goal of the trial was to evaluate treatment with alirocumab, a monoclonal antibody targeting PCSK9, compared with ezetimibe among participants with high cardiovascular risk on maximum tolerated statin therapy.

Contribution to the Literature: This trial showed that among patients with high cardiovascular risk treated with statin therapy, alirocumab resulted in a large reduction in LDL-C.